Table 1.
Demographic and baseline data.
| n = 655 | Mean ± SD, n (%) |
|---|---|
| Demographics | |
| Age (years) | 51.44 ± 10.45 |
|
| |
| Sex, n (%) | |
| Male | 478 (73%) |
| Female | 177 (27%) |
| BMI | 29.13 ± 2.80 |
| Diabetes mellitus | 180 (27.4) |
| Hypertension | 87 (13.3) |
|
| |
| Laboratory data | |
| Albumin (gm/dL) | 4.08 ± 0.54 |
| Bilirubin (mg/dL) | 0.83 ± 0.45 |
| INR | 1.11 ± 0.13 |
| ALT (IU/l) | 65.10 ± 51.89 |
| AST (IU/l) | 88.98 ± 39.60 |
| Hb (gm/dl) | 14.08 ± 1.77 |
| WBCs (×10³/mm³) | 6.35 ± 2.12 |
| Platelets (×10³/mm³) | 178.17 ± 71.63 |
| HCV RNA (IU/ml) | 1526115.6 ± 2650113 |
| Fasting blood glucose (mg/dL) | 112 ± 55 |
|
| |
| Baseline LSM (kPa) | 18.4 ± 14.45 |
| Noncirrhotics | 8.29 ± 2.31 |
| Cirrhotics | 29.66 ± 14.25 |
|
| |
| State of fibrosis according to LSM | |
| F0-1 | 116 (17.7%) |
| F2 | 117 (17.9%) |
| F3 | 109 (16.6%) |
| F4 (cirrhosis) | 313 (47.8%) |
| Child–Pugh class A | 208 (66.4%) |
| Child–Pugh class B | 105 (33.6%) |
| Child–Pugh class C | 0 (0%) |
|
| |
| Treatment regimen, n (%) | |
| SOF + RBV | 302 (46.1%) |
| SOF + SIM | 28 (4.3%) |
| SOF + DCV ± RBV | 325 (49.6%) |
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin; WBCs, white blood count; HCV RNA, hepatitis C virus ribonucleic acid; INR, international normalized ratio; kPa, kilo Pascal; LSM, liver stiffness measurement; SOF, sofosbuvir; RBV, ribavirin; SIM, simiprevir; DCV, daclatasvir.